erlotinib has been researched along with Cancer of Liver in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Z; Duan, ZA; Han, TJ; Li, YQ; Li, Z; Wang, L; Yang, F; Zhao, WJ | 1 |
| Abd El Hamid, MK; Abdelrahman, MH; Abou-Salim, MA; Elgazwi, SM; Elshaier, YAMM; Halaweish, F; Shaaban, MA | 1 |
| Abd El-Meguid, EA; Awad, HM; El Kerdawy, AM; Moustafa, GO; Naglah, AM | 1 |
1 review(s) available for erlotinib and Cancer of Liver
| Article | Year |
|---|---|
Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Topics: Antineoplastic Agents; Benzothiazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Liver Neoplasms; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
2 other study(ies) available for erlotinib and Cancer of Liver
| Article | Year |
|---|---|
Phosphoramidate protides of five flavones and their antiproliferative activity against HepG2 and L-O2 cell lines.
Topics: Amides; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Flavones; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Phosphoric Acids | 2016 |
Design and synthesis of pyrazolo[3,4-d]pyrimidines: Nitric oxide releasing compounds targeting hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Drug Design; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Models, Molecular; Nitric Oxide Donors; Pyrazoles; Pyrimidines | 2017 |